COR logo Cencora +
Cencora
+

Cencora (COR) Business News

Track Cencora in real time with a live news feed covering Cencora stock news, official press releases, company announcements, and an archive of historical Cencora news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

PRNewsWire

10:21 AM | Thursday | May 28, 2026

news photo
Loading...

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Read full article redirect
10:21 AM | Thursday | May 28, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

PRNewsWire

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Read full article arrow
News Thumbnail
10:21 AM | Thursday | May 28, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

PRNewsWire

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Read full article arrow
News Thumbnail
12:11 PM | Wednesday | May 27, 2026

CAH vs. COR: Which Healthcare Distributor Stock Is the Better Buy?

Zacks Investment Research

CAH and COR are betting big on specialty pharma, but Cardinal Health???s stronger growth, raised outlook, and broader expansion may set it apart.

Read full article arrow
News Thumbnail
6:55 AM | Wednesday | May 27, 2026

Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer

Business Wire

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, 2026. Ms.
Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously announced. Mr. Cleary will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Ms.
Boratto is an experienced pub.

Read full article arrow
News Thumbnail
5:43 PM | Tuesday | May 26, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

GlobeNewsWire

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

Read full article arrow
News Thumbnail
5:15 PM | Friday | May 22, 2026

Cencora Inc (COR) Stock Up 3.6% and Still Undervalued -- GF Score: 79/100

GuruFocus

On May 22, 2026, Cencora Inc (COR) shares rose by 3.6% to a current price of $274.91. The stock has experienced a 52-week range between $244.82 and $377.
54, ref

Read full article arrow
News Thumbnail
5:13 PM | Thursday | May 21, 2026

Cencora revises forecast for 2026, approves $2 billion share buyback

Reuters

U.S. drug distributor Cencora on Thursday raised the lower end of its fiscal ​2026 earnings forecast citing recent ‌share repurchases, and also approved a new $2 billion stock buyback plan.

Read full article arrow
News Thumbnail
4:30 PM | Thursday | May 21, 2026

Cencora Announces Updated Fiscal Year 2026 Financial Outlook

Business Wire

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today updated its fiscal year 2026 financial guidance as a result of recent opportunistic share repurchases. Cencora now expects adjusted diluted earnings per share to be in the range of $17.70 to $17.
90, up from the previous range of $17.65 to $17.90. The opportunistic share repurchases completed in May align with the Company's previously disclosed expectation that it will repurchase $1.0 billion in shares of common stock by the end.

Read full article arrow
News Thumbnail
3:33 PM | Thursday | May 21, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

PRNewsWire

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Read full article arrow
News Thumbnail
5:29 PM | Tuesday | May 19, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

GlobeNewsWire

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

Read full article arrow
News Thumbnail
2:53 PM | Monday | May 18, 2026

COR Investors Have Opportunity to Join Cencora, Inc. Fraud Investigation with the Schall Law Firm

GlobeNewsWire

LOS ANGELES, May 18, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or “the Company”) (NYSE: COR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Read full article arrow
News Thumbnail